Table 3.

Predictors of High-Dose Beta-Blocker Use Among 2592 Pre-Match Patients with Heart Failure with Ejection Fraction ≥50% and Heart Rate ≥70 Beats/Minute Receiving Beta-Blockers with Dosage Data

	Multivariable-adjusted odds ratio* (95% confidence interval)
Age ≥80 years	0.67 (0.56–0.81); p<0.001
Female	0.99 (0.82–1.19); p=0.893
African American	1.31 (1.00–1.72); p=0.048
Atrial fibrillation	1.26 (1.04–1.52); p=0.016
Chronic obstructive pulmonary disease	0.75 (0.61–0.91); p=0.005
Discharge prescription for ACE inhibitor or ARBs**	1.23 (1.02–1.48); p=0.029
Discharge prescription for hydralazine	1.93 (1.22–3.05); p=0.005
Discharge prescription for calcium channel blockers	1.32 (1.08–1.61); p=0.008
Serum creatinine (increments of 0.1 mg/dL)	1.10 (1.03–1.17); p=0.008
Hospital, Northeast region	1.33 (1.07–1.65); p=0.009
Hospital, Academic	1.18 (0.98–1.41); p=0.079

^*Also adjusted for hypertension, coronary artery disease, diabetes mellitus, cerebrovascular disease, peripheral vascular disease, discharge systolic blood pressure ≥120 mm Hg, discharge heart rate ≥80 beats per minute, left ventricular ejection fraction, and discharge prescription for diuretics

^**ACE=Angiotensin-converting enzyme; ARB=angiotensin receptor blocker